Genentech Researchers Report on Notorious Ras Oncogene’s Inhibitors at ASCB Annual Meeting

A chink in the molecular armor of Ras has been uncovered by a drug discovery team at Genentech, Inc.,.

A chink in the molecular armor of Ras has been uncovered by a drug discovery team at Genentech, Inc.,. The most commonly occurring oncogene, is a gene that when mutated, possesses the potential of causing cancer in humans.

The chink, binding pocket of "functional significance" on the Ras oncoprotein could provide the long-sought attack point for a therapeutic agent, making the "undruggable" Ras oncogene "druggable," the researchers reported at the American Society for Cell Biology's 51st Annual Meeting in Denver.

"Magnetic" Gene Found in Cancer-ridden Family
Researchers have recently found a genetic mutation that makes some individuals more prone to colorectal, bowel and other cancers.

The first human oncogene to be identified, Ras is mutated in about 25% of all human tumors. For cancer patients, the presence of an activated Ras oncogene is a poor prognosis marker.

Ras has a molecular on-off switch, activated by the energy transfer molecule GTP. In the "on" position, the oncogene activates critical cell signaling pathways involving cell proliferation, cell migration and cell differentiation, all of which are in hyper-drive in tumors.

To develop a drug that would switch off Ras, scientists needed a binding site, an opening in the Ras oncoprotein to which the docking mechanism of a therapeutic molecule could attach.

Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
Aromatase inhibitors like anastrozole are more effective in treating postmenopausal women with hormone receptor-positive early breast cancer than tamoxifen.

At the ASCB meeting, Joachim Rudolph, Ph.D., Weiru Wang, Ph.D., and Guowei Fang, Ph.D., of Genentech, a member of the Roche Group, reported that they identified such a binding pocket by fragment-based lead discovery, a screening process that sorted through 3,300 small molecule compounds. Nuclear magnetic resonance (NMR) spectroscopy was used to pinpoint molecules with even a weak affinity for binding to Ras oncoproteins. The researchers identified 25 compounds, none of which knocked out the oncoprotein.

However, NMR spectroscopy revealed that the 25 compounds were binding to the same location on the Ras oncoprotein. The researchers determined that the binding pocket was not static but could be enlarged once the ligand from the small molecule engaged it, providing researchers an opening for engineering the next generation of compounds.

Lack of Overall Survival Improvement Linked to Toxicity of Aromatase Inhibitors
Study says the toxicities associated with aromatase inhibitors (AIs) may explain the lack of overall survival improvement compared with tamoxifen

Fang said that even the weak ligands formed by these compounds interfered with the Ras oncoprotein by blocking an enzyme, abbreviated SOS, that is required for activating the oncoprotein.

"The small molecules identified here represent the first generation of Ras inhibitors that directly prevent Ras activation," Fang said.

Certain antidepressant drugs associated with pronounced suicidal tendencies
Toronto: Antidepressants such as Prozac, Paxil and Zoloft, prescribed to the elderly, has shown a tendency of inducing suicidal thoughts in its recipients,

Source-Eurekalert